Aerosolized liposomal Amphotericin B: A potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients

Pediatric Pulmonology

Volumn 49, Issue 6, 2014, Pages 574-580

  Kamalaporn, Harutai ^a   Leung, Kitty ^b   Nagel, Mark ^c   Kittanakom, Saranya ^d   Calvieri, Battista ^e   Reithmeier, Reinhart A F ^d   Coates, Allan L ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c TRUDELL MEDICAL INTERNATIONAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

AeroEclipse ; aerosolized liposomal amphotericin B; breath actuated nebulizer; invasive pulmonary Aspergillosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; LIPOSOME; AEROSOL; AMPHOTERICIN B; ANTIFUNGAL AGENT;

AEROSOL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; GEL FILTRATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOME NEBULIZER; IMMUNOCOMPROMISED PATIENT; LASER DIFFRACTION; LUNG ASPERGILLOSIS; NEBULIZATION; PARTICLE SIZE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; DRUG EFFECTS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INVASIVE PULMONARY ASPERGILLOSIS; NEBULIZER;

ADMINISTRATION, INHALATION; AEROSOLS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNOCOMPROMISED HOST; INVASIVE PULMONARY ASPERGILLOSIS; MICROSCOPY, ELECTRON; NEBULIZERS AND VAPORIZERS;

EID: 84900010976     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22856     Document Type: Article

References (31)

1. Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, Trittin A, Kern WV, Boenisch O, Bosse D, Lenz K, Ludwig WD, Hiddemann W, Siegert W, Beyer J,. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 93: 3654-3661.
2. Allen SD, Sorensen KN, Nejdl MJ, Durrant C, Proffit RT,. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994; 34: 1001-1013.
3. Olson JA, Adler-Moore JP, Schwartz J, Jensen GM, Proffitt RT,. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006; 50: 2122-2131.
4. Gavalda J, Martin MT, Lopez P, Gomis X, Ramirez JL, Rodriguez D, Len O, Puigfel Y, Ruiz I, Pahissa A,. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother 2005; 49: 3028-3030.
5. Ruijgrok EJ, Vulto AG, Van Etten EW,. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother 2001; 48: 89-95.
6. Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, van Etten EW, Vulto AG,. Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity. J Pharm Pharmacol 2005; 57: 1289-1295.
7. Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, van Etten EW, Vulto AG,. Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50: 1852-1854.
8. Ruijgrok EJ, Vulto AG, Van Etten EW,. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats. J Pharm Pharmacol 2000; 52: 619-627.
9. Dennis JH, Hendrick DJ,. Design characteristics for drug nebulizers. J Med Eng Technol 1992; 16: 63-68.
10. Lambros MP, Bourne DW, Abbas SA, Johnson DL,. Disposition of aerosolized liposomal amphotericin B. J Pharm Sci 1997; 86: 1066-1069.
11. Diot P, Rivoire B, Le Pape A, Lemarie E, Dire D, Furet Y, Breteau M, Smaldone GC,. Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Respir J 1995; 8: 1263-1268.
12. Monforte V, Roman A, Gavalda J, Bravo C, Tenorio L, Ferrer A, Maestre J, Morell F,. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001; 20: 1274-1281.
13. Ruffini E, Baldi S, Libertucci D, Solidoro P, Di Marzio P, Cavallo A, Mancuso M,. Aerosolized liposomal amphotericin B: a novel and effective treatment for Aspergillus infections in lung transplant recipients. Proceedings of the 42nd ICAAC (Interscience Conferrence on Antimicrobial Agents and Chemotherapy) Meeting, San Diego, CA. Sept 2002; Abstract#M-1237.
14. Monforte V, Roman A, Gavalda J, et al. Pharmacokinetic and efficacy of nebulized AmBisome in lung transplantation. Proceedings of the 44th ICAAC (Interscience Conferrence on Antimicrobial Agents and Chemotherapy) Meeting, Washington DC. Oct/Nov 2004; Abstract#M-1042.
15. Corcoran TE, Venkataramanan R, Mihelc KM, Marcinkowski AL, Ou J, McCook BM, Weber L, Carey ME, Paterson DL, Pilewski JM, Mccurry KR, Husain S,. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006; 6: 2765-2773.
16. Monforte V, Roman A, Gavalda J, Lopez R, Pou L, Simo M, Aguade S, Soriano B, Bravo C, Morell F,. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003; 75: 1571-1574.
17. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Lowenberg B, Vulto A, Lugtenburg PJ, De Marie S,. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008; 46: 1401-1408.
18. Leung K, Louca E, Coates AL,. Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency. Chest 2004; 126: 1619-1627.
19. MacIntyre NR, Mitchell JP, Nagel MW, Coppolo D,. Similar delivery of amphotericin lipid complex is possible at one-half dose via a breath-actuated nebulizer compared to a continuously operating nebulizer. Poster presentation in ATS (American Thoracic Society) Conferrence, San Diego. May 22-24, 2005.
20. Mitchell JP, Nagel MW, MacIntyre NR,. A mechanically operated breath-actuated nebulizer enables both improved control of dosing and delivery efficiency. Accepted for Drug Delivery to the Lungs-16, Edinburgh-December 7-9, 2005.
21. Mitchell JP, Nagel MW, Nichols S, Nerbrink O,. Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers. J Aerosol Med 2006; 19: 409-433.
22. Kwong WT, Ho SL, Coates AL,. Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow Marple personal cascade impactor. J Aerosol Med 2000; 13: 303-314.
23. Coates AL, Denk O, Leung K, Ribeiro N, Chan J, Green M, Martin S, Charron M, Edwardes M, Keller M,. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. Pediatr Pulmonol 2011; 46: 401-408.
24. O'Callaghan C, Clark AR, Milner AD,. Why nebulise for more than five minutes ? Arch Dis Child 1989; 64: 1270-1273.
25. Kawabata M, Onda M, Mita T,. Effect of aggregation of amphotericin B on lysophosphatidylcholine micelles as related to its complex formation with cholesterol or ergosterol. J Biochem 2001; 129: 725-732.
26. Byrne B, Carmody M, Gibson E, Rawlings B, Caffrey P,. Biosynthesis of deoxyamphotericins and deoxyamphoteronolides by engineered strains of Streptomyces nodosus. Chem Biol 2003; 10: 1215-1224.
27. Coates AL, Green M, Leung K, Chan J, Ribeiro N, Ratjen F, Charron M,. A comparison of amount and speed of deposition between the PARI LC STAR(R) jet nebulizer and an investigational eFlow(R) nebulizer. J Aerosol Med Pulm Drug Deliv 2011; 24: 157-163.
28. McCormack P, Southern KW, McNamara PS,. New nebulizer technology to monitor adherence and nebulizer performance in cystic fibrosis. J Aerosol Med Pulm Drug Deliv 2012; 25: 307-309.
29. Elhissi A, Gill H, Ahmed W, Taylor K,. Vibrating-mesh nebulization of liposomes generated using an ethanol-based proliposome technology. J Liposome Res 2011; 21: 173-180.
30. Manunta MD, McAnulty RJ, Tagalakis AD, Bottoms SE, Campbell F, Hailes HC, Tabor AB, Laurent GJ, O'Callaghan C, Hart SL,. Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium. PLoS ONE 2011; 6: e26768.
31. Katz SL, Adatia I, Louca E, Leung K, Humpl T, Reyes JT, Coates AL,. Nebulized therapies for childhood pulmonary hypertension: an in vitro model. Pediatr Pulmonol 2006; 41: 666-673.